Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1242135 | 1.00 | PTGS2 (0.37) | PTGS2PTGS1GSRALDH1A1 | |
| SCHEMBL636596 | 0.95 | PTGS2 (0.34) | PTGS2PTGS1GSR | |
| SCHEMBL1244636 | 0.95 | PTGS2 (0.34) | PTGS2PTGS1GSR | |
| SCHEMBL1244648 | 0.95 | PTGS2 (0.34) | PTGS2PTGS1GSR | |
| SCHEMBL7448724 | 0.89 | PTGS2 (0.36) | PTGS2PTGS1GSRALDH1A1 | |
| SCHEMBL4370859 | 0.89 | PTGS2 (0.36) | PTGS2PTGS1GSRALDH1A1 | |
| SCHEMBL1243887 | 0.89 | PTGS2 (0.36) | PTGS2PTGS1GSRALDH1A1 | |
| SCHEMBL17554625 | 0.86 | GSR (0.30) | GSR | |
| SCHEMBL4369900 | 0.81 | PTGS1 (0.32) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL9803325 | 0.81 | PTGS2 (0.34) | PTGS2PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121665-B1 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-22 | — | — | EP | disclosed |
| US-7880014-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7880014-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2121665-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | Merck and Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-20080194660-A1 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| WO-2008076246-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076247-A2 | NITRODERIVATIVES AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194660-A1 | Angiotensin II receptor antagonists | AGTR1, AGTR2, REN | PTGS2 1456/4885PTGS1 1479/4885GSR 1878/4885 |
| US-20100152259-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, REN | PTGS2 1359/4885PTGS1 1397/4885GSR 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.